title: Subfoveal serous retinal detachment in patients with uveitic macular edema.
abstract: OBJECTIVE
  To assess the clinical characteristics and effect on visual acuity (VA) of a subfoveal serous retinal detachment (SRD) associated with macular edema (ME) in patients with uveitis.
  
  
  METHODS
  Clinical and optical coherence tomograph characteristics were retrospectively assessed in 37 patients with uveitic ME with a subfoveal SRD (case individuals) and 61 patients with uveitic ME without a subfoveal SRD (control individuals), matched for uveitis location, sex, and age. Scans of the case and control individuals took place between September 19, 2003, and July 21, 2008.
  
  
  RESULTS
  Patients with a subfoveal SRD had a shorter history of uveitis (P = .03) and ME (P = .03) and a lower VA (P = .003). Mean total retinal thickness (TRT) in cases exceeded that of controls (449 vs 326 μm; P < .001). The median subfoveal SRD duration was 2 months, and 29 of 36 SRDs (81%) had disappeared at the 3-month follow-up examination. The improvement in VA and the decrease in TRT after 3 months were better in the subfoveal SRD group than in the control group (P = .001 for VA and P = .001 for TRT), resulting in similar VA and TRT after 3 months.
  
  
  CONCLUSIONS
  A subfoveal SRD was associated with lower VA and developed typically in the early stages of uveitis and ME. The subfoveal SRD and VA reacted favorably to treatment with periocular and systemic steroids and/or oral acetazolamide.
authors.affiliation: Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands. A.Ossewaarde-vanNorel@umcutrecht.nl.
authors.forename: Jeannette
authors.initials: J
authors.lastname: Ossewaarde-van Norel
authors.forename: Elize M
authors.initials: EM
authors.lastname: Berg
authors.forename: Karen M
authors.initials: KM
authors.lastname: Sijssens
authors.forename: Aniki
authors.initials: A
authors.lastname: Rothova
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D005584:Fovea Centralis; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008269:Macular Edema / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012163:Retinal Detachment / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014605:Uveitis / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D000086:Acetazolamide